Vor Biopharma enters sales agreement with William Blair and RBC Capital Markets
VOR•Vor Biopharma entered a sales agreement with William Blair and RBC Capital Markets on Oct. 30, 2026, and may offer up to $150 million of common stock, according to an SEC filing.
1. Sales agreement
Vor Biopharma entered a sales agreement with William Blair and RBC Capital Markets on Oct. 30, 2026. The company may offer common stock with an aggregate offering price of up to $150 million, an SEC filing showed.
